Sutro Biopharma (STRO) EBT Margin (2017 - 2025)
Sutro Biopharma recorded quarterly EBT Margin of 709.76% in Q4 2025, down 21.0% quarter-over-quarter from 586.58% in Q3 2025, and down 175649.0% year-over-year from N/an in Q4 2024.
Sutro Biopharma's EBT Margin history runs 9 years deep, the most recent figure standing at 709.76% for Q4 2025.
- In Q4 2025, EBT Margin fell 175649.0% year-over-year to 709.76%; the TTM figure through Dec 2025 stood at 210.58% (changed N/A YoY), while the FY2025 annual figure was 186.55%, changed N/A from the prior year.
- EBT Margin came in at 709.76% for Q4 2025 at Sutro Biopharma, down from 586.58% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 1046.73% in Q4 2024 to a low of 1146.05% in Q1 2025.
- A 5-year average of 290.25% and a median of 360.34% in 2021 frame the typical range for EBT Margin.
- Across the five-year window, EBT Margin surged 100551 bps in 2024 and tumbled 175649 bps in 2025, its largest moves.
- Sutro Biopharma's EBT Margin stood at 357.85% in 2021, then decreased by 12 bps to 400.76% in 2022, then soared by 110 bps to 41.22% in 2023, then surged by 2440 bps to 1046.73% in 2024, then plunged by 168 bps to 709.76% in 2025.
- According to Business Quant data, EBT Margin over the past three periods registered 709.76%, 586.58%, and 18.07% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.40% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 41.95% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.05% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 18.99% |
| 10 | Sutro Biopharma | 242.87 Mn | 242.87 Mn | - | -709.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -709.76% |
| Sep 30, 2025 | -586.58% |
| Jun 30, 2025 | -18.07% |
| Mar 31, 2025 | -1,146.05% |
| Dec 31, 2024 | 1,046.73% |
| Sep 30, 2024 | -572.62% |
| Jun 30, 2024 | -269.72% |
| Mar 31, 2024 | -447.52% |
| Dec 31, 2023 | 41.22% |
| Sep 30, 2023 | -280.34% |
| Jun 30, 2023 | -368.55% |
| Mar 31, 2023 | -391.79% |
| Dec 31, 2022 | -400.76% |
| Sep 30, 2022 | -77.50% |
| Jun 30, 2022 | -83.68% |
| Mar 31, 2022 | -663.22% |
| Dec 31, 2021 | -357.85% |
| Sep 30, 2021 | -362.83% |
| Jun 30, 2021 | -21.93% |
| Mar 31, 2021 | -134.17% |
| Dec 31, 2020 | -336.87% |
| Sep 30, 2020 | -70.91% |
| Jun 30, 2020 | -200.53% |
| Mar 31, 2020 | -273.98% |
| Dec 31, 2019 | -130.82% |
| Sep 30, 2019 | -105.17% |
| Jun 30, 2019 | -131.05% |
| Mar 31, 2019 | -192.21% |
| Dec 31, 2018 | -7.82% |
| Sep 30, 2018 | -130.64% |
| Jun 30, 2018 | -202.33% |
| Mar 31, 2018 | -207.94% |
| Dec 31, 2017 | -382.77% |
| Sep 30, 2017 | -7.07% |